the aid library

LIST OPTIONS

Filter

3680

Sort by:

Direction:

Download (237)

View PDF (432)

"Heile Welt" Podcast
recommended

Pia Sophie Schüler; Madeleine Sittner (2019) C1

Medizin in Deutschland – alles heile Welt?! Könnte man schnell denken, wenn man im Studium nur Krankheiten und Therapiekonzepte lernt. Wir sind uns aber sicher, Medizin ist mehr und wollen mit “Heile Welt” den Kontext bieten. “Heile Welt” ist euer Podcast über medizinische Themen mit pol... more

Download (118)

View PDF (1141)

Sangath

(2019) CC

Sangath is a non-governmental, not-for-profit organisation committed to improving health across the life span by empowering existing community resources to provide appropriate physical, psychological and social therapies. Its primary focus areas include child development, adolescent and youth health... more

Download (88)

View PDF (1964)

Résilience PSY

Josse, E. (2019) CC

Evelyne Josse est psychologue clinicienne diplômée de l’Université Libre de Bruxelles. Elle est maître de conférences associée à l’université de Lorraine (Metz). Formée à l’hypnothérapie éricksonienne, à l’EMDR (Eye Movement Desensitization and Reprocessing), à la thérapie br... more

Download (1805)

View PDF (1323)

Selection and Use of Essential Medicines 2021
recommended

World Health Organization WHO (2021) C_WHO

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo... more

Download (76)

View PDF (119)

COVID-19: Verbreitung verlangsamen - Epidemiologisches Bulletin

Robert-Koch-Institut RKI (2020) C2

Bei vielen schwer erkrankten Menschen muss mit einer im Verhältnis zu anderen schweren ARE längeren Behandlung mit Beatmung/zusätzlichem Saürstoffbedarf gerechnet werden. Da weder eine Impfung noch eine spezifische Therapie derzeit zur Verfügung stehen, müssen alle Massnahmen darauf ausgericht... more

Download (80)

View PDF (123)

Ambulante patienten-zentrierte Vorausplanung für den Notfall: Ein Leitfaden aus Anlass der Covid-19-Pandemie

Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin e.V. (2020) C2

Dieser Leitfaden soll ambulant tätige Ärztinnen und Ärzten in der für diese Klärung erforderlichen qualifizierten Gesprächsführung sowie in derkorrespondierenden, krisentauglichen Dokumentation unterstützen. Dazu werden nach einer Vorbemerkung (II.) Hinweise zur Therapiezielklärung (III.), ... more

Download (149)

View PDF (185)

Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019)

World Health Organization WHO (2020) C_WHO

Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report... more

Download (64)

View PDF (575)

Wichtige Informationen zur Tuberkulose für alle, die aus der Ukraine oder anderen Ländern nach Deutschland kommen

Deutsches Zentralkomitte zur Bekämpfung der Tuberkulose DZK (2022) CC

Das DZK ist eine Nichtregierungsorganisation (NGO), die sich in Deutschland um die Bedürfnisse von Tuberkulose-Patientinnen und -Patienten kümmert und die nationalen Empfehlungen zur Prävention und Therapie herausgibt.

Download (227)

View PDF (166)

WHO standard acupuncture point locations in the Western Pacific region

World Health Organization (WHO) (2009) C_WHO

Acupuncture has been practised for more than 2500 years in the Western Pacific Region and has become a global therapeutic method in recent decades. However, it was reportedthat acupuncturists differed by up to 25% in the acupuncture points they used, raising doubts and uncertainty regarding the effi... more

Download (113)

View PDF (159)

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il... more

Download (115)

View PDF (159)

Traitements contre la maladie à virus Ebola
recommended

Organisation Mondiale de la Santé OMS (2022) C_WHO

Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (21)

View PDF (19)

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

Abola, M. T. B.; Golledge, J.; Miyata, T. et al. Journal of Atherosclerosis and Thrombosis (2020) CC

Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod... more

Download (17)

View PDF (16)

An overview of heart failure in low- and middle-income countries

Agbor, V.N.; Ntusi, N.A.B.; Noubiap, J.J. Cardiovascular Diagnosis and Therapy (2020) CC

Heart failure (HF) is a global public health concern with disproportionate socioeconomic, morbidity and mortality burden on low- and middle-income countries (LMICs). This review summarises contemporary data on the demographic and clinical characteristics, aetiologies, treatment, economic burden and ... more

Download (11)

View PDF (9)

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Kleindorfer, .O.; Towfighi, A.; Chaturvedi, S. et al. American Heart Association (2021) CC

Each year, ≈795 000 individuals in the United States experience a stroke, of which 87% (690 000) are ischemic and 185 000 are recurrent.1 Approximately 240 000 individuals experience a transient ischemic attack (TIA) each year.2 The risk of recurrent stroke or TIA is high but can be mitiga... more

Download (15)

View PDF (17)

Prevention and management of CVD in LMICs: why do ethnicity, culture, and context matter?

Anand, S.; Bradshaw, C.; Prabhakaran, D. BMC Medicine (2020) CC

Background Low- and middle-income countries now experience the highest prevalence and mortality rates of cardiovascular disease. Main text While improving the availability and delivery of proven, effective therapies will no doubt mitigate this burden, we posit that studies evaluating cardiovasc... more

Download (19)

View PDF (10)

Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries

Fowkes, G.F.; Forster, R.B.; Levin, C.E. et al. International Angiology (2017) CC3

INTRODUCTION: Lower extremity peripheral artery disease (PAD) is increasing in prevalence in low- and middle-income countries creating a large health care burden. Clinical management may require substantial resources but little consideration has been given to which treatments are appropriate for les... more

Download (13)

View PDF (16)

Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk

World Health Organization WHO (2007) C_WHO

Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera... more

Download (99)

View PDF (98)

Leitfaden zum sensibilisierten Umgang mit Patient*innen

Sara Grzybek Queermed Deutschland (2024) CC

Diskriminierungssensibler Umgang mit Patient*innen ermöglicht allen Menschen gesundheitliche Hilfe aufzusuchen. Im Gesundheitssystem gibt es Menschen, die weniger sichtbar sind als andere. Damit sich Ärzt*innen, Therapeut*innen, Pflegende und andere im Gesundheitssystem Tätige stärker mit indiv... more

Download (20)

View PDF (19)

Access to essential respiratory medications remains elusive in LMICs

Karmali, D.; Siddharthan, T. (2022) CC

Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme... more

"Heile Welt" Podcast recommended

Selection and Use of Essential Medicines 2021 recommended

Therapeutics for Ebola virus disease recommended

Traitements contre la maladie à virus Ebola recommended

"Heile Welt" Podcast
recommended

Selection and Use of Essential Medicines 2021
recommended

Therapeutics for Ebola virus disease
recommended

Traitements contre la maladie à virus Ebola
recommended